Rapid Micro Biosystems Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 98 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rapid Micro Biosystems Inc's Score
Industry at a Glance
Industry Ranking
98 / 205
Overall Ranking
261 / 4521
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rapid Micro Biosystems Inc Highlights
StrengthsRisks
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 63.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.05M.
Undervalued
The company’s latest PE is -3.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.36M shares, decreasing 7.42% quarter-over-quarter.
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.